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Several antigens, defined by monoclonal antibodies raised
against colorectal cancer have been shown to be elevated in
the serum in gastrointestinal cancer. A few of these anti-
bodies have been used as the basis of commercial tests; they
include CA 19.9 (Magnani et al., 1983), CA 50 (Cooper et
al., 1988) and CA 195 (Bhargava et al., 1989), all of which
show elevation in advanced colorectal and pancreatic cancer.
Serum levels of these antigens tend to be highly correlated.
Metzgar et al. (1982) raised monoclonal antibodies to
human pancreatic adenocarcinoma cells, one of which,
DUPAN-2, had a high positive reaction with antigens
secreted by pancreatic cancer patients. Using a competitive
assay, studies in the United States (Metzgar et al., 1984;
Mahvi et al., 1986) and in Japan (Sawabu et al., 1986)
indicated a high positivity rate for DUPAN-2 in pancreatic
and biliary tract carcinomas but low positivity in colorectal
and gastric cancer. An enzyme immunoassay (EIA) was
subsequently developed in Japan (Sakurabayashi et al., 1986)
and this kit has recently become available for evaluation in
Europe. This report describes our experience of DUPAN-2
measurements in pancreatic cancer and diseases that are
encountered clinically during the diagnostic work-up of a
patient with suspected pancreatic cancer.
The investigation was made on 154 patients with cancer,
they included pancreatic cancer (68), gastric cancer (40), liver
metastases from breast, colorectal, lung cancer and other
sites (46). In addition, 67 sera were measured from patients
with benign gastrointestinal diseases that included cirrhosis
and chronic hepatitis (20), pancreatitis (20), choleolithiasis (6)
and other benign diseases (21). The diagnosis of pancreatic
cancer was confirmed by histology or cytology in 61 patients,
in the remainder the diagnosis was on the basis of radio-
logical evidence from endoscopic retrograde cholangiopan-
creatography (ERCP), computed tomography or laparotomy.
The sera were stored at -20°C until they were assayed.
DUPAN-2-EIA was supplied by Medgenix Diagnostics,
Brussels, as a kit developed by Kyowa Medex Ltd, Japan.
The test kit is a sandwich EIA that uses a 96 well microtitre
plate coated with anti DUPAN-2 monoclonal antibody.
After incubation with samples or standards the wells are
washed and incubated with enzyme labelled anti DUPAN-2,
after a further washing the substrate (methyl carbamoyl-3,7
dimethyl amino 1OH phenothiazine) is added. The colour
produced is directly proportional to the DUPAN-2 concen-
tration. The kit has a dynamic range of 0- 1,600 U ml-'; the
upper limit of normal is 100 U ml-1. CA 19.9 was measured
with ELSA-CA 19.9 kits from CIS.
The frequency distribution of DUPAN-2 levels with re-
spect to the upper limit of normal 100 U ml ' and a dis-
criminant level of 400 U ml' suggested by Sawabu et al.
(1986) is shown in Table I. The highest positivity ratio was
observed in pancreatic cancer. Sixty-one of the patients with
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pancreatic cancer were staged into resectable (10), non-
resectable but without metastases (29), and metastatic (22)
the median DUPAN-2 levels were 240, 350 and 10,000 U
ml-' respectively and when a cut off of 400 U ml1' was used
30, 52 and 72% respectively were positive.
Although the median level rises with increasing tumour
burden there was a very wide range of values for each of
these surgical stages with lower and upper limits of 14 and
142,000 U ml-' respectively.
In 46 patients with pancreatic cancer where the survival
times were known the correlation between DUPAN-2 level at
presentation and survival was r = 0.302, T = -2.1016,
P = 0.041 (Spearman rank) test. Subdividing the patients into
DUPAN-2 levels <400, or > 400 Ulml-' then the median
survival times were 130 days (range 4-319) and 70 days
(range 5-333) respectively.
In a comparison of CA 19.9 and DUPAN-2, elevation of
CA 19.9 (>37 U ml-') was observed in 36/49 (73%) car-
cinoma of the pancreas 76% of whom showed a raised
DUPAN-2 (> 100 U ml-'); 22/38 (58%) of patients with
hepatic metastases from sites other than the pancreas had a
raised CA 19.9, compared to 4/38 (10.5%) with a raised
DUPAN-2. In gastric cancer 5/40 (12.5%) had a raised
CA 19.9 and 4/40 (10%) a raised DUPAN-2. There was a
positive correlation between DUPAN-2 and CA 19.9 in pan-
creatic cancer (r=0.6208, P<0.001), but in 7/40 (17.5%)
the CA 19.9 levels were much lower than the DUPAN-2, and
in three patients the CA 19.9 was >50 U ml-' when the
DUPAN-2 was not increased.
Previous investigations of DUPAN-2 (Sawabu et al., 1986;
Takemori et al., 1987; Mahvi et al., 1985) have shown that
this marker can show a wide range of serum levels in pan-
creatic cancer that appear to be related to the behaviour of
individual tumours rather than a strict correlation with
tumour bulk or dissemination. In our series there was a
tendency for the median level to rise as the tumours pro-
gressed from resectable to non-resectable but with wide intra-
individual variation within each stage.
When the 400 U ml1' cut-off is applied, as suggested by
Table I DUPAN-2 percentageofraised values in surgical andmedical
diseases
Positive ratio %
Disease No. > 100 UmlP >400 Uml'
Pancreatic cancer 68 82 59
Gastric cancer 40 10 2.5
Liver metastases 46 15 6.5
(excluding pancreatic cancer)
Pancreatitis 20 30 10
Gall stones 6 83 50
(with jaundice)
Benign liver disease 20 50 10
(without jaundice)
Jaundice various 21 43 9
medical causes
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Japanese investigators, then 59% of the pancreatic cancers in
our series gave a positive DUPAN-2 at diagnosis compared
to 50% of 167 patients reported in the Japanese studies.
However, this 400 U ml1 discriminant for DUPAN-2 did
not distinguish the poor from average survival. These fea-
tures suggest that the expression of DUPAN-2 is limited to
certain tumours; Japanese studies have clearly shown a high
DUPAN-2 positivity in bile duct cancer 44% of 92 patients,
and primary hepatoma 55% of 73 patients. DUPAN-2 and
CA 19.9 are not well correlated; the correlation coefficient in
all cases of pancreas cancer in our study was 0.621, and in 77
cancers reported by Sawabu et al. (1986) it was 0.628. The
noticeable difference between DUPAN-2 and the other
carbohydrate antigens is the much lower incidence of
DUPAN-2 elevation in metastases in the liver from colorectal
cancer and primaries outside the gastrointestinal tract.
CA 19.9 levels >37 U ml1 are found in 15-36% ofpatients
with benign pancreatic, liver and biliary diseases (Jalanko et
al., 1984); whilst in this study DUPAN-2 was positive
(>1OOUml-') in 30-83% of similar benign diseases. As
with the other carbohydrate antigens, jaundice due to benign
disease, can produce a mild increase of DUPAN-2 which is
generally below the 400 U ml' cut-off.
DUPAN-2 provides a serum marker of pancreatic and bile
duct cancer which appears to have an improved specificity
for these cancers compared to other markers. A 400 U ml-'
cut-off will reduce the sensitivity of the test, but if the upper
limit of normal (100 U ml-') is used as the cut-off it greatly
reduces the specificity of this tumour marker. This study and
those made in Japanese patients indicate that CA 19.9 and
DUPAN-2 are sufficiently independent to complement each
other and cannot be used as substitutes one for the other.
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